, Tracking Stock Market Picks
Enter Symbol:
Sorrento Therapeutics, Inc. (SRNE) [hlAlert]

up 47.34 %

Sorrento Therapeutics, Inc. (SRNE) rated Buy with price target $40 by Aegis Capital

Posted on: Tuesday,  Dec 3, 2013  10:25 AM ET by Aegis Capital

Aegis Capital rated Buy Sorrento Therapeutics, Inc. (NASDAQ: SRNE) on 12/03/2013, when the stock price was $9.04. Since
then, Sorrento Therapeutics, Inc. has gained 47.35% as of 01/20/2016's recent price of $13.32.
If you would have followed this Aegis Capital's recommendation on SRNE, you would have gained 47.34% of your investment in 778 days.

Sorrento Therapeutics, Inc. (STI) is a development-stage biopharmaceutical company focused on applying its technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic and infectious diseases. STI had not generated any revenue during the year ended December 31, 2009. The Company?s objective is to construct a human antibody library and, either independently or through one or more partnerships with pharmaceutical or biopharmaceutical organizations, to identify drug development candidates derived from this library. As of December 31, 2009, the Company had not developed any product candidates for commercialization. On September 21, 2009, QuikByte Software, Inc. (QuikByte) acquired STI in a reverse merger (the Merger). Pursuant to the Merger STI became a wholly owned subsidiary of QuikByte.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/3/2013 10:25 AM Buy
9.04 40.00
as of 12/13/2013
1 Week up  8.46 %
1 Month up  4.86 %
3 Months   
1 YTD up  4.86 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy